Full Press Release Details
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting
AMLX Positive Sentiment
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Key Takeaway: Amylyx Pharmaceuticals will present topline data from its Phase 3 LUCIDITY clinical trial of Avexitide, aimed at treating post-bariatric hypoglycemia. This presentation is scheduled for the ObesityWeek 2026 Annual Meeting, highlighting the company's advancements in addressing this condition. The event is expected to attract significant attention in the obesity treatment community.
Market Sentiment Analysis
POSITIVE FACTORS
- Amylyx Pharmaceuticals is presenting data from a Phase 3 trial.
- The trial focuses on Avexitide for post-bariatric hypoglycemia.
- The presentation will take place at a significant event, ObesityWeek 2026.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+173%
120-day peak, hindsight
Typical move
5.6%
average across 4 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
AMX0035
Phase 2 · Wolfram Syndrome
Frequently Asked Questions
What is the LUCIDITY clinical trial?
The LUCIDITY clinical trial is a Phase 3 study evaluating Avexitide for post-bariatric hypoglycemia.
When will the data be presented?
The topline data will be presented at the ObesityWeek 2026 Annual Meeting.
What condition does Avexitide target?
Avexitide is aimed at treating post-bariatric hypoglycemia.
Who is conducting the LUCIDITY trial?
The trial is being conducted by Amylyx Pharmaceuticals.